drug
isaralgagene civaparvovec
Phase 2updated 3mo agoby $SGMO SANGAMO THERAPEUTICS, INC
Phase 2community read0 votes
all catalysts(0)
nothing on the calendar yet
News(3)
- PTC takes a chance on Sangamo’s Fabry disease gene therapyWall Street analysts view the deal as a risky, high-reward bet on a treatment that’s nearing a possible regulatory approval and could be superior to existing medications.biopharma_dive · 7d ago
- Bankrupt Sangamo offloads assets to Lilly, PTC in $161M salePTC Therapeutics emerged as the winning bidder over Astellas for Sangamo Therapeutics’ Fabry disease gene therapy, while Eli Lilly is purchasing the biotech’s prion disease program and several plat…biospace · 7d ago
- PTC’s $211M bid wins Sangamo auction, teeing up ‘special opportunity’ to enter Fabry marketPTC Therapeutics has struck a deal to buy Sangamo Therapeutics’ Fabry disease program for $111 million upfront, outbidding Astellas and TerSera Therapeutics for the near-approval gene therapy. Sang…fiercebiotech · 8d ago
Data sources
last refreshed 6m ago
Found something off?
comments(0)
5-min edit window · permanent after that